Faenza A, Fuga G, Bertelli R, Scolari M P, Buscaroli A, Stefoni S
Department of Kidney Transplant Surgery, S. Orsola University Hospital, Bologna, Italy.
Transplant Proc. 2008 Jul-Aug;40(6):1833-8. doi: 10.1016/j.transproceed.2008.05.078.
On all kidney waiting lists the 10% to 20% of patients who have antibodies against more than 80% of a panel of HLA antigens (panel reactive antibody [PRA] >80%) are difficult to transplant. The best solution for these patients is to find a compatible donor, ideally a full match, who yields a negative crossmatch test (CMX). If this is not possible, desensitization treatment (high-dose) intravenous immunoglobulin (IVIG) or plasmapheresis (PP) + low-dose IVIG is possible with good results in living donor kidney transplantation mainly if the antibody titer is low. It may also be offered to patients awaiting cadaveric donors too after a long waiting time; however, when applied for several months, it has the obvious disadvantage of giving the patient the risk for long-lasting immunologic weakness without the certitude of finding a kidney. In one of our recent cases of combined liver plus kidney transplantation, a positive CMX became negative 8 hours after the liver operation; the kidney was transplanted with a good result which lasted over 3 years. This observation suggested the possibility of a quick desensitization protocol in selected patients with a large (but not strong) immunization who probably are the majority. Patients sensitized to IVIG and with low titer PRA could be given a single PP + low-dose IVIG (what can be done within the time limit of cadaveric donor kidney transplantation) with good probability of turning an initial positive CMX to negative with the possibility of performing the operation and the advantage of giving the immunosuppression only when the kidney is present.
在所有肾脏等待名单上,有10%至20%的患者体内存在针对一组HLA抗原中80%以上抗原的抗体(群体反应性抗体[PRA]>80%),这些患者很难进行移植。对于这些患者,最佳解决方案是找到一个相容的供体,理想情况下是完全匹配的供体,其交叉配型试验(CMX)结果为阴性。如果无法做到这一点,脱敏治疗(高剂量)静脉注射免疫球蛋白(IVIG)或血浆置换(PP)+低剂量IVIG也是可行的,在活体供肾移植中效果良好,主要是在抗体滴度较低时。对于等待尸体供肾的患者,经过较长等待时间后也可提供这种治疗;然而,当应用数月时,它有一个明显的缺点,即让患者面临长期免疫功能低下的风险,同时又不确定能否找到肾脏。在我们最近的一例肝肾联合移植病例中,肝移植术后8小时CMX由阳性转为阴性;随后进行了肾移植,效果良好,持续了3年多。这一观察结果提示,对于可能占大多数的、免疫反应强烈(但并非极强)的特定患者,有可能采用快速脱敏方案。对IVIG敏感且PRA滴度较低的患者可进行单次PP+低剂量IVIG治疗(这可以在尸体供肾移植的时间限制内完成),很有可能将最初的阳性CMX转为阴性,从而有可能进行手术,并且只有在有肾脏时才给予免疫抑制,具有一定优势。